Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.
2.

Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G.

Exp Cell Res. 2005 Apr 1;304(2):604-19. Epub 2005 Jan 21.

PMID:
15748904
3.

Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.

Sassen A, Diermeier-Daucher S, Sieben M, Ortmann O, Hofstaedter F, Schwarz S, Brockhoff G.

Breast Cancer Res. 2009;11(4):R50. doi: 10.1186/bcr2339. Epub 2009 Jul 22.

4.

Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.

Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.

Breast Cancer Res. 2007;9(4):R50.

5.

[Breast cancer--known receptors, new pathways?].

Bürger H.

Verh Dtsch Ges Pathol. 2006;90:124-7. German.

PMID:
17867588
6.

Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin.

Anastasi S, Sala G, Huiping C, Caprini E, Russo G, Iacovelli S, Lucini F, Ingvarsson S, Segatto O.

Oncogene. 2005 Jun 30;24(28):4540-8.

PMID:
15856022
8.

ErbB receptors and signaling pathways in cancer.

Hynes NE, MacDonald G.

Curr Opin Cell Biol. 2009 Apr;21(2):177-84. doi: 10.1016/j.ceb.2008.12.010. Epub 2009 Feb 7. Review.

PMID:
19208461
9.

Prognostic value of ERBB family mRNA expression in breast carcinomas.

Bièche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R.

Int J Cancer. 2003 Sep 20;106(5):758-65.

10.
11.
12.

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.

Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K.

Clin Cancer Res. 2006 Jul 1;12(13):4103-11.

13.

Progression and treatment of HER2-positive breast cancer.

Davoli A, Hocevar BA, Brown TL.

Cancer Chemother Pharmacol. 2010 Mar;65(4):611-23. doi: 10.1007/s00280-009-1208-1. Epub 2009 Dec 20.

PMID:
20087739
15.

[Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].

Dieras V, Vincent-Salomon A, Degeorges A, Beuzeboc P, Mignot L, de Cremoux P.

Bull Cancer. 2007 Mar;94(3):259-66. Review. French.

PMID:
17371768
16.

ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.

Ginestier C, Adélaïde J, Gonçalvès A, Repellini L, Sircoulomb F, Letessier A, Finetti P, Geneix J, Charafe-Jauffret E, Bertucci F, Jacquemier J, Viens P, Birnbaum D.

Oncogene. 2007 Nov 1;26(50):7163-9. Epub 2007 May 21.

PMID:
17525746
17.

Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases.

Stern DF.

Breast Cancer Res. 2000;2(3):176-83. Epub 2000 Mar 25. Review.

18.

[Targeting ErbB receptors in breast cancer].

Fumoleau P, Campone M, Coudert B, Mayer F, Favier L, Ferrant E.

Bull Cancer. 2007;94(7 Suppl):F147-70. Review. French.

PMID:
17964992
19.

HER2 expression as a potential marker for response to therapy targeted to the EGFR.

Emlet DR, Schwartz R, Brown KA, Pollice AA, Smith CA, Shackney SE.

Br J Cancer. 2006 Apr 24;94(8):1144-53.

20.

Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women.

Singh LC, Chakraborty A, Mishra AK, Devi TR, Sugandhi N, Chintamani C, Bhatnagar D, Kapur S, Saxena S.

Med Oncol. 2012 Jun;29(2):539-46. doi: 10.1007/s12032-011-9952-6. Epub 2011 Apr 29.

PMID:
21528410
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk